EMERYVILLE, Calif., May 01, 2017 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has made significant progress in the development of its healthy sweetener product technology and expects industrial production to occur in 2018. Amyris is successfully making a No Compromise® sweetener where the company is on track to be the low cost leader at industrial scale production with a natural-like sweetener with very low calories that is sustainably sourced. Amyris’s target is to sell the world’s leading sweetener at a lower cost than sugar without any negative taste. Consumers love soda but hate sugar – Amyris wants to make soda taste the same and be healthy. The company expects this product opportunity in partnership with its partner to deliver over $100 million in annual revenue by 2020.
“Our focus on supplying the lowest cost, best performing products into Health & Nutrition and Personal Care markets by partnering with the leading brands has very strong momentum,” said John Melo Amyris President & CEO. “Our efforts to give the consumer sustainably sourced, best performing products without dangerous ingredients is really starting to payoff. We believe we have the leading market position for sustainable, healthy sweeteners and we are very excited about helping the world transition away from unhealthy sugars and accelerate the use of healthy sweeteners by providing the consumer a better taste experience and our partners better economics.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the company’s expectations that it will be able to successfully launch a sweetener product with industrial production in 2018, that it is on track to be the low cost leader for such product and that this product opportunity is anticipated to deliver over $100 million in revenue by 2020, as well as the company’s belief that it has the leading market position for sustainable, healthy sweeteners) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc.
Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 [email protected] [email protected]


AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Google Secures Pentagon AI Deal for Classified Projects 



